<DOC>
	<DOCNO>NCT02541695</DOCNO>
	<brief_summary>Although exist diarrhoeagenic Escherichia coli ( E. coli ) challenge model already suitable dietary intervention current form , characterization working-mechanism attenuate strain optimization study design enable investigator well select ingredient affect key pathophysiological process . The aim CORAL study characterize increase discriminative power diarrhoeagenic E. coli challenge model .</brief_summary>
	<brief_title>Characterization Resistance Against Live-attenuated Diarrhoeagenic E. Coli</brief_title>
	<detailed_description>Primary Objective : In CORAL study investigator want determine whether increase inoculation dose diarrhoeagenic Escherichia coli ( E. coli ) 5E10 Colony Forming Units ( CFU ) ( day 14 ) addition second challenge 1E10 CFU ( day 35 ) result increase effect-size duration measurable outcome expansion relevant clinical biomarker readouts challenge model . Secondary Objective : By extensive biomarker transcriptome analysis blood fecal sample , investigator aim explore work mechanism non-toxin produce diarrhoeagenic E. coli strain kinetics host response infection . In addition , investigator want determine whether add extend fast addition standardize even meal , prior inoculation day , result decrease between-subject variation . Study design : The CORAL study parallel 7-weeks intervention study . Subjects randomly assign one two inoculation dosage live attenuate diarrhoeagenic E. coli ( n=20 per group ) . Subjects instruct maintain usual pattern physical activity habitual food intake , standardize dietary calcium intake . After standardized evening meal overnight fast , subject orally infected live , attenuate , diarrhoeagenic E. coli ( strain E1392-75-2A ; collection NIZO food research ; dose either 1E10 CFU ( n=22 ) 5E10 CFU ( n=22 ) study day 14 ) . At study day 35 , standardize even meal overnight fast , subject receive second inoculation 1E10 CFU ETEC vaccine ( n=44 ) . At various time point diarrhoeagenic E. coli challenge online diary kept record food drink consumption ass dietary macronutrient intake . Moreover , subject report information stool consistency , frequency severity symptom . At various time point diarrhoeagenic E. coli challenge venous blood ( complete ) stool sample collect . Blood fecal sample collect quantify several infection- immune system marker . Study population : Healthy male subject , 18-55 year age fulfil inclusion criterion none exclusion criterion participate CORAL study . Intervention : At study day 14 35 , standardize even meal overnight fast , subject receive inoculation diarrhoeagenic E. coli ( 1E10 CFU ( n=22 ) 5E10 CFU ( n=22 ) study day 14 ; 1E10 CFU ( n=40 ) study day 35 ) Subjects instruct maintain habitual diet , except dairy intake . Dairy high calcium content contribute significantly total daily calcium intake . These dietary guideline limit calcium intake average 500 mg/day . From previous study , know calcium significantly reduce gastro-intestinal symptom induce E. coli strain . Main study parameter : 1 . Percentage faecal dry weight ( % determine freeze-drying ) Secondary study parameter : 1 . Total faecal wet weight ( faecal weight g/day ) 2 . Time first diarrhoeal stool ( report subject online diary ) 3 . Stool consistency ( Bristol Stool Scale report subject online diary 4 . Number stools Bristol Stool Scale &gt; 4 ( Bristol Stool Scale report subject online diary ) 5 . Stool frequency ( Stools per day report subject online diary ) 6 . Incidence duration WHO-defined diarrhoea ( Calculated Bristol Stool Scale Stool frequency report subject online diary ) 7 . The incidence , duration severity Gastro-intestinal symptom ( Gastro-intestinal Symptom Rating Scale report subject online diary ) . 8 . In addition , study contains explorative phase consist biomarker transcriptome analysis , order explore identify mechanism kinetics host response infection .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Diarrhea</mesh_term>
	<mesh_term>Bacterial Infections</mesh_term>
	<mesh_term>Gastroenteritis</mesh_term>
	<mesh_term>Escherichia coli Infections</mesh_term>
	<criteria>Inclusion criterion : 1 . Ability follow verbal write instruction ; 2 . Age 18 55 year ; 3 . Availability internet connection ; 4 . BMI ≥20 ≤27 kg/m2 ; 5 . Healthy assess NIZO food research medical questionnaire ; 6 . Male subject ; 7 . Signed informed consent ; 8 . Voluntary participation ; 9 . Willing accept disclosure financial benefit participation study authority concern ; 10 . Willing accept use encode data , include publication , confidential use storage data least 15 year ; 11 . Willing comply study procedure ; 12 . Willingness abstain high calcium containing product . 13 . Willingness abstain medication contain acetaminophen , aspirin , ibuprofen , nonsteroidal antiinflammatory drug , ( OTC ) antacids antimotility agent ( eg , loperamide ) three day , 3 day diarrhoeagenic E. coli challenge . 14 . Willingness abstain alcoholic beverage three day , three day diarrhoeagenic E. coli challenge . 15 . Willingness give blood donation start 1 month prior study start entire study ; Exclusion criterion : 1 . Disease GI tract , liver , bile bladder , kidney , thyroid gland ( selfreported ) ; 2 . Diarrhoeagenic E.coli strain ( use study ) detect fecal sample screening ; 3 . Evidence current excessive alcohol consumption nontherapeutic drug ( ab ) use ) ; 4 . Evidence IgA deficiency ( serum IgA &lt; 7 mg/dL limit detection assay ) . 5 . High titer serum antibody CFAII diarrhoeagenic E.coli strain ( use study ) screening ; 6 . History microbiologically confirm ETEC cholera infection last 3 year . 7 . Known allergy follow antibiotic : ciprofloxacin , trimethoprimsulfamethoxazole , penicillin . 8 . Mental status incompatible proper conduct study ; 9 . Not general practitioner , allow disclosure participation general practitioner allow inform general practitioner abnormal result . 10 . Occupation involve handle ETEC Vibrio cholerae currently , past 3 year . 11 . Participation clinical trial include blood sample and/or administration substance start 1 month prior study start entire study ; 12 . Personnel NIZO food research , partner first second degree relative ; 13 . Reported average stool frequency &lt; 1 &gt; 3 per day ; 14 . Symptoms consistent Travelers ' Diarrhoea concurrent travel country ETEC infection endemic ( develop world ) within 3 year prior dose , OR plan travel endemic country length study . 15 . Use antibiotic , norit , laxative ( till 6 month prior inclusion ) , cholestyramine , antacid H2 receptor antagonists proton pump inhibitor immune suppressive agent ( till 3 month prior inclusion ) ; 16 . Vaccination ingestion ETEC , cholera , E coli heat labile toxin within 3 year prior inclusion ; 17 . Vegetarians vegan</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Experimental challenge trial</keyword>
</DOC>